Piramal Pharma Q4 FY26 Results: Date, Estimates 2026

Why Piramal Pharma’s Q4 FY26 print matters

Piramal Pharma (NSE: PPLPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. The March quarter is closely tracked because the company has previously highlighted that Q4 tends to be its biggest quarter, with a higher share of annual sales and profits. For FY26, investors are watching for signs that operating conditions have stabilised after a weak quarter that included pressure in the CDMO business and profitability volatility. Analysts’ published estimates for Q4 FY26 cluster around a potential return to positive profit after tax (PAT). Alongside earnings, the company’s balance sheet and interest cost burden remain central to the investment debate due to debt linked to capacity expansion. The outcome also matters for sentiment because the stock has traded well below its 52-week high in recent months.

Piramal Pharma Q4 results date and board meeting agenda

Piramal Pharma has scheduled its Q4 FY26 results for May 2026 (expected). The company has indicated that its board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026. The same meeting is also expected to consider a final dividend recommendation. For market participants, this combination of audited numbers and a dividend decision typically increases focus on cash flow and balance sheet commentary. Any final dividend recommendation will be read alongside management’s stance on debt reduction and capital allocation.

Street estimates: revenue, PAT and EBITDA margin ranges

Analyst estimates for Q4 FY26 revenue stand at Rs 2,400-2,600 Cr. PAT expectations are in the range of Rs 28-55 Cr, with margin projections of EBITDA at 16-19%. These estimates reflect sector trends and company-specific factors flagged by analysts, including seasonality in some business lines and the expectation of operational improvements. The projections are not company guidance, and actual results may differ from these estimates. Still, the range provides a framework for what the market is positioned for heading into the results window.

A quick snapshot: estimates vs the recent base quarter

The Q4 estimates are being built off a weaker Q3 FY26 base, where multiple sources in the provided data point to pressure on earnings and margins. The company’s Q3 FY26 commentary cited weaker CDMO orders and inventory destocking. It also pointed to regulatory delays affecting parts of the critical care portfolio. A key near-term question is whether Q4 shows a cleaner earnings number with fewer exceptional impacts, as some analyst notes expect.

Key driver 1: expected PAT recovery and the “clean” earnings question

A central expectation going into Q4 is a return to PAT positive after a loss in Q3 FY26. The provided data includes a Q3 FY26 net loss figure of Rs 18 Cr in one section, while another section reports a consolidated net loss of Rs 136.19 Cr after accounting for Rs 41 Cr in exceptional items. Against that backdrop, analysts are focusing on whether Q4 delivers a positive PAT print in the Rs 28-55 Cr range. The same dataset notes that a positive PAT print of around Rs 30-55 Cr would be important for investor sentiment. Explanations cited for a potential recovery include CDMO revenue growth, operational improvement in CHG, and the absence of exceptional items. Investors will also compare the reported EBITDA margin against the 16-19% projection range, particularly after Q3’s reported margin contraction to 11%.

Key driver 2: CDMO demand, RFP momentum and execution

CDMO remains a swing factor because Q3 FY26 was impacted by a 9% fall in the CDMO segment, with CDMO revenue listed at Rs 1,166 Cr versus Rs 1,278 Cr a year earlier. Management commentary in the provided information attributed the softness to inventory corrections in one large on-patent commercial product and slower early-stage order inflows in H1 FY26. The same source also cited inconsistent recovery in US biopharma funding and uncertainties around global trade policy as contextual headwinds. At the same time, the company said it was seeing a significant pick-up in RFPs and early signs of recovery in order inflows since October 2025, supported by improved biopharma funding and increased M&A activity in the US. In Q4, investors will look for evidence in the numbers and commentary that this RFP momentum is translating into revenue conversion.

Key driver 3: India consumer healthcare seasonality

Piramal’s India consumer healthcare business, which sells OTC brands such as Lacto Calamine, Little’s, and Littles Care, is positioned as a steady domestic revenue stream. Q4 FY26 will reflect summer-season demand for skin care and baby care products, based on the seasonality discussed in the provided context. The same dataset notes that growth in this segment supports the overall revenue diversification story. In Q3 FY26, consumer healthcare was reported to have grown 30%, helped by new launches and e-commerce. Investors will assess whether this momentum holds into Q4 and how much it can offset volatility in export-linked or project-based businesses.

Balance sheet focus: debt, interest expense and free cash flow

Debt remains a major monitorable item because Piramal Pharma carries significant debt from its CDMO capacity expansion, as noted in the provided text. The same context flags that Q4 FY26 will reflect free cash flow generation and progress on debt reduction. Any improvement in net debt levels driven by CDMO contract milestones and CHG recoveries would reduce financial risk and could support credit metrics, according to the discussion. The dataset also highlights that elevated debt levels generate significant interest expenses, and that financial risk remains elevated until EBITDA grows enough to cover debt service more comfortably. In Q3 FY26, interest expense was listed at Rs 89 Cr, with depreciation at Rs 213 Cr, underscoring the drag that fixed costs can exert when revenue is soft.

Stock price context: where PPLPHARMA is trading into results

Piramal Pharma was trading at Rs 182 as of early April 2026, according to the provided information. The stock’s 52-week high is listed at Rs 268 and the 52-week low at Rs 142. At Rs 182, the stock is stated to be 32% below its 52-week high. This context matters because results-driven repricing often depends on whether earnings prints exceed what is already priced in. The same dataset flags that PAT above Rs 40 Cr combined with CDMO revenue acceleration would be viewed as the strongest possible outcome for sentiment, while also emphasising operational watchpoints such as US FDA inspection outcomes and CHG margin improvement.

Longer-term financial context from available annual data

The provided profit and loss table shows revenue from operations (net) rising from Rs 2,899.75 Cr in Mar 21 to Rs 5,202.56 Cr in Mar 25. Total revenue is listed at Rs 3,136.78 Cr in Mar 21 and Rs 5,493.06 Cr in Mar 25. Profit for the period in the same table is listed at Rs 571.50 Cr for Mar 21 and Rs 691.40 Cr for Mar 25, with intervening values shown for Mar 22 to Mar 24. This history indicates expansion in the revenue base over several years, though quarterly volatility in FY26 has drawn attention to business mix and project timing. Separately, the dataset includes FY24 commentary that net debt to EBITDA improved from 5.6x at the start of the year to 2.9x at the end of FY24, highlighting why leverage metrics remain in focus.

What to watch on result day beyond headline numbers

Beyond revenue and PAT, investors typically scrutinise segment commentary, margin bridges, and the presence or absence of exceptional items. For Piramal Pharma, the Q3 narrative included inventory destocking, regulatory delays from the Digwal facility affecting inhalation anesthesia for ex-US markets, and cost-optimisation efforts that partly offset lower revenues. Q4 commentary will be watched for whether these issues have eased and whether the company is seeing sustained improvement in order inflows. Any update tied to US FDA inspection outcomes and CHG margin improvement will also be tracked, as highlighted in the provided text. Finally, the board’s consideration of a final dividend recommendation may shape market interpretation of cash generation and confidence.

Conclusion

Piramal Pharma’s Q4 FY26 results, expected in May 2026, are set up as a key checkpoint for profitability and operating recovery. Street estimates imply revenue of Rs 2,400-2,600 Cr, EBITDA margin of 16-19%, and PAT of Rs 28-55 Cr, with the market especially sensitive to a clean return to PAT positive after a weak Q3. Alongside the income statement, debt reduction progress and interest cost trends will remain central for investors. The company’s board meeting agenda includes approval of audited financial statements and consideration of a final dividend recommendation, which will add to the focus on cash flow and balance sheet discipline.